Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 280

Total 280 documents found.

  •  
  • Takeda Expands International Operations Leadership July 30, 2010
  • Osaka, Japan, July 30, 2010 -Takeda Pharmaceutical Company Limited ("Takeda") today announced that effective August 1, 2010 the International Operations organization will be further strengthened with the appointment of a Senior Vice President (SVP) responsible for ex-Japan Asia commercial activities. This change will further enhance the company’s structure to accelerate Takeda’s global strategies and enable the management team in each region to most effectively address the local business environment.
  • Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors June 18, 2010
  • Osaka and Tokyo, Japan, June 18, 2010 --- Takeda Pharmaceutical Company Limited (Osaka, President and CEO: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd. (Tokyo; President and CEO: Haruo Naito) jointly announced today that they have received approval from the Japanese Ministry of Health, Labor and Welfare for additional indications for Helicobacter pylori (“H. pylori”) eradication by concomitant therapy with three proton pump inhibitors, lansoprazole, omeprazole, and rabeprazole sodium, marketed in Japan under four brand names. This concomitant therapy consists of a proton pump inhibitor, amoxicillin hydrate, and either clarithromycin or metronidazole, and is indicated for the eradication of H. pylori in gastric MALT lymphoma(*1), idiopathic thrombocytopenic purpura(*2) (“ITP”) and the stomach after endoscopic resection of early stage gastric cancer.
  • Takeda Introduces ‘Cisco TelePresence’ (Advanced Videoconferencing System) September 10, 2009
  • Osaka, Japan, September 10, 2009 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced today that it has introduced Cisco TelePresence™, －an advanced videoconferencing system providing both high-resolution visuals and a high-quality audio environment. Cisco TelePresence™ was provided by Cisco Systems G.K. (Headquarters: Minato-ku, Tokyo; President & CEO: Edzard J.C. Overbeek, “Cisco”), and IBM Japan, Ltd. (Headquarters: Minato-ku, Tokyo; President: Takayuki Hashimoto; NYSE: IBM, “IBM Japan”) provided support to introduce this videoconfereincing system at Takeda. .
  • Terumo and Takeda to Co-promote Takeda’s Ethical Narcotic Formulations September 3, 2009
  • Tokyo and Osaka, Japan, September 3, 2009 - Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Akira Takahashi, “Terumo”) and Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced jointly today that the two companies will commence in coming October the co-promotion of ethical narcotic formulations that Takeda is manufacturing and marketing in Japan.
  • Agreements Concluded for “SELTOUCH ® Pap 70, 140”Transdermal Absorption-type Analgesic and Anti-inflammatory Agent July 27, 2009
  • Wyeth K.K. (Headquarters: Shinagawa-ku, Tokyo, President & Representative Director Michael Goettler, “WKK”), ASKA Pharmaceutical Co., Ltd (Headquarters: Minato-ku, Tokyo, President, Representative Director Takashi Yamaguchi, “ASKA”) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, President & CEO Yasuchika Hasegawa, “Takeda”) today announced changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, “SELTOUCH ® Pap 70, 140” (“SELTOUCH”). WKK and ASKA signed an agreement in which the sales right for SELTOUCH is granted to ASKA. ASKA and Takeda also signed an agreement in which the sales and promotion of SELTOUCH are entrusted to Takeda.
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
  • Approval of an Additional Indication of Combination Therapy of Glufast and Insulin Sensitizer in Japan February 24, 2009
  • Matsumoto, Japan & Osaka, Japan, February 24, 2009 --- Kissei Pharmaceutical Co., Ltd (President, C.E.O. Mutsuo Kanzawa, “Kissei”) and Takeda Pharmaceutical Company Limited (President, Yasuchika Hasegawa, “Takeda”) announced today that an additional indication of “combination therapy with insulin sensitizer” for Glufast (geneic name: mitiglinide) 5mg tablet and 10mg tablet, which is being co-marketed by Kissei and Takeda, was approved by the regulatory authorities in Japan.
  • ULORIC® (TMX-67, febuxostat) Receives FDA Approval forthe Chronic Management of Hyperuricemia in Patients with Gout February 14, 2009
  • Tokyo and Osaka, Japan, February 14, 2009 – Teijin Pharma Limited (Head office: Chiyoda-ku, Tokyo; President: Osamu Nishikawa, hereafter “Teijin Pharma”) and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, hereafter “Takeda”) announced today that on February 13, 2009, Teijin Pharma’s U.S. licensee for febuxostat and Takeda’s wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., (Head office: Deerfield, Illinois) received FDA marketing approval for ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout. Takeda Pharmaceuticals North America is the sole developer and marketer of the product, ULORIC in the U.S.
  • Transfer of Shares of Mitsui Takeda Chemicals, Inc. from Takeda to Mitsui Chemicals April 3, 2006
  • Osaka, Japan, --- Takeda Pharmaceutical Company Limited ("Takeda", President & COO : Yasuchika Hasegawa) announced today that all of Takeda's shares of Mitsui Takeda Chemicals Inc. ("MTCI", President: Masafumi Kataita) had been transferred to Mitsui Chemicals, Inc. ("MCI", President: Kenji Fujiyoshi) on April 1. Upon transfer of shares, MTCI changed its name to Mitsui Chemicals Polyurethanes, Inc.
  • Transfer of Shares of BASF Takeda Vitamin K.K. from Takeda to BASF Japan January 5, 2006
  • OSAKA, JAPAN --- Takeda Pharmaceutical Company Limited ("Takeda", President & COO: Yasuchika Hasegawa) announced today that all of Takeda's shares of BASF Takeda Vitamin K.K. ("BTV", President: Akihiko Sato) were transferred to BASF Japan Ltd. ("BASF Japan", President: Tomoyoshi Naruo) on January 4, 2006, based on the original joint venture agreement between BASF Japan and Takeda concluded in January 2001.
  • ACTOplus met™ (pioglitazone HCl and metformin HCl) Now Available in U.S. Pharmacies
    New product combines two widely used diabetes medications in a single tablet, offering patients a convenient option November 1, 2005
  • LINCOLNSHIRE, Ill., November 1, 2005 −Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met™(pioglitazone HCl and metformin HCl) is now available by prescription in pharmacies across the United States for the treatment of type 2 diabetes. This is the second Takeda product launch in the United States this year, following the approval of ROZEREM™ (ramelteon) on July 22, 2005.ACTOplus met™ combines ACTOS®(pioglitazone HCl) and metformin, two widely used diabetes medications, in a single tablet. ACTOS directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. "Takeda is pleased to provide ACTOplus met, an important addition to the ACTOS family of products," said Mark Booth, president of Takeda. "Since most people with type 2 diabetes take multiple therapies to reach their target glucose levels, we believe that this combination pill will offer an effective, convenient new treatment option for patients."To offer physicians greater flexibility in treating their patients' needs, ACTOplus met will be available in two dosages of pioglitazone/metformin − 15 mg/500 mg and 15 mg/850 mg − both of which are to be given once a day or in divided doses not exceeding the maximum recommended daily doses of pioglitazone 45 mg and metformin 2,550 mg, according to the approved labeling.According to the American Diabetes Association, diabetes affects more than 18 million people, and type 2 diabetes is the most common form of the disease. Both ACTOS and metformin are widely used medications in the treatment of type 2 diabetes and both have a known safety profile. Combining these medications may provide patients with an easier way to take the two drugs, as they are already often prescribed together to help manage the disease.
  • ROZEREM™ (ramelteon) Now Available in U.S. Pharmacies
    First and only non-scheduled prescription sleep medication September 26, 2005
  • LINCOLNSHIRE, Ill., September 26 − Takeda Pharmaceuticals North America, Inc. today announced that ROZEREM™(ramelteon) 8-mg tablets are now available by prescription in pharmacies across the U.S. for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM is the first prescription insomnia medication with a new therapeutic mechanism of action in 35 years, and can be prescribed for long-term use in adults.ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse and dependence in clinical studies. As a result, ROZEREM is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA). With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as controlled substances by the DEA, most as Schedule IV drugs."The availability of ROZEREM represents the second Takeda-discovered-and-developed product to reach physicians and patients in our brief history," said Mark Booth, president of Takeda Pharmaceuticals North America. "We are excited to be able to offer an important new option for people living with insomnia that has not shown the potential for abuse or dependence."ROZEREM has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates 24-hour, or circadian, rhythms including the sleep-wake cycle.
  • Transfer of Shares of Takeda Schering-Plough Animal Health K.K. from Takeda to Schering-Plough June 28, 2005
  • OSAKA, JAPAN --- Schering-Plough K.K. ("SPKK", President: Masao Torii) and Takeda Pharmaceutical Company Limited ("Takeda", President & COO: Yasuchika Hasegawa) announced today that all of Takeda's shares of Takeda Schering-Plough Animal Health K.K. ("TSA", President and Representative Director: Leopoldo Nanni) will be transferred to Schering-Plough ("SP") as of end of June 2005, based on the agreement concluded in March 2000.
  • Partial Transfer of Wyeth K.K. Equity from Takeda to Wyeth April 7, 2005
  • Madison N.J., U.S.A. and Osaka, Japan −−− Wyeth (Headquarters: Madison, N.J., U.S.A.; President, Chief Executive Officer and Chairman: Robert Essner, "Wyeth") and Takeda Pharmaceutical Company Limited (Headquarters:, Osaka; President:Yasuchika Hasegawa, "Takeda") agreed that Takeda, which holds a 40 percent share, would transfer a 10 percent share of Wyeth K.K. (Headquarters:, Tokyo; President: Rune Bremberg) to Wyeth with the transfer to be completed today.
  • Takeda to Transfer its Life-environmental Business to Osaka Gas March 30, 2005
  • OSAKA, JAPAN −−− Osaka Gas Co., Ltd. ("Osaka Gas", President: Hirofumi Shibano) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa) jointly announced today the transfer of shares of Takeda's five subsidiaries and affiliates engaged in life-environmental business to Osaka Gas Chemicals Co., Ltd. ("Osaka Gas Chemicals", President: Mitsuo Endo), a subsidiary of Osaka Gas. Such five companies include Japan EnviroChemicals, Ltd. ("Japan EnviroChemicals" President: Atsuo Kobayashi), a wholly owned subsidiary of Takeda.
  • Takeda to Acquire Syrrx February 7, 2005
  • Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda", President and Chief Operating Officer: Yasuchika Hasegawa) announced today that Takeda and Syrrx Inc. (San Diego, CA, "Syrrx", Chairman of the Board: Samuel D.Colella) agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary closing conditions. Upon successful completion of the transaction, which is anticipated to occur in the first quarter of 2005, Syrrx will become a subsidiary of Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top